Every material Form 8-K Abbott Laboratories has filed with the SEC since November 20, 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Abbott plans to spin off its global Nutrition business, which has about $8.5 billion in annual sales, into a separate public company through a tax-free distribution to Abbott shareholders. Abbott expects the separation to be completed by the end of 2027, subject to conditions including regulatory approvals and final board approval, and says it will not affect Abbott's 2026 guidance.
Nutrition business has approximately $8.5 billion in annual sales, about 16,000 employees and 14 manufacturing sites
Abbott will keep sales of approximately $42 billion after the separation
Separation expected to be completed by the end of 2027; Abbott expects one-time transaction charges, not yet quantified
Daniel Salvadori will become chief executive officer of the new Nutrition company
Abbott reported third-quarter 2026 results on October 21, 2026, with net sales up 14.5% to $13.0 billion, aided by the Exact Sciences acquisition completed March 23, 2026. GAAP diluted EPS fell 43.6% to $0.53 after specified items, including about $670 million of legal settlements and $841 million of intangible amortization, while adjusted diluted EPS rose 9.2% to $1.42. The company tightened its full-year 2026 adjusted EPS guidance to $5.50 to $5.55, reaffirming the midpoint, which matters to shareholders because reported profit fell sharply even as sales and adjusted earnings grew.
Third-quarter net sales were $13,013 million, up 14.5% reported and 7.0% on a comparable basis.
GAAP diluted EPS was $0.53, down from $0.94 a year earlier; adjusted diluted EPS was $1.42, up from $1.30.
Specified items included about $670 million in legal settlements and $841 million in intangible amortization.
Full-year 2026 adjusted diluted EPS guidance was narrowed to $5.50 to $5.55, with the midpoint reaffirmed; projected comparable sales growth is approximately 6.0%.
Abbott agreed to resolve the Gill lawsuit and necrotizing enterocolitis claims for about 2,000 other infants for an aggregate of approximately $670 million, instead of continuing its appeal or paying about $600 million on the Gill judgment plus interest. The company states the agreements are a compromise and not an admission of liability, but the payment is a sizable cost, and roughly 1,700 lawsuits involving about 12,700 infants remain pending.
Gill case: July 2024 Missouri jury verdict of $495 million, affirmed by the Missouri Court of Appeals in May 2026.
Settlement: aggregate amount of approximately $670 million covering the Gill case and claims for about 2,000 additional infants.
Alternative cited: paying approximately $600 million, the Gill judgment plus accrued interest to date.
Remaining litigation: roughly 1,700 lawsuits involving claims for about 12,700 individual infants.
Abbott reported second-quarter 2026 net sales of $12.6 billion, up 13.0% from a year earlier, with comparable sales growth of 4.8%. It raised its full-year 2026 adjusted diluted EPS guidance to $5.45 to $5.60, but GAAP diluted EPS fell to $0.53 from $1.01 after large specified-item charges, including $658 million of intangible amortization.
Q2 2026 net sales were $12.593 billion, up 13.0% reported and 4.8% comparable; Diagnostics rose 42.3% reported, boosted by the Exact Sciences acquisition completed March 23, 2026.
Adjusted diluted EPS was $1.31, up from $1.26; GAAP diluted EPS was $0.53, down from $1.01, and GAAP net earnings were $928 million versus $1.779 billion.
Full-year 2026 adjusted diluted EPS guidance was raised to $5.45 to $5.60 from $5.38 to $5.58; comparable sales growth guidance of 6.5% to 7.5% was reaffirmed.
Abbott returned $2.1 billion to shareholders in the quarter via dividends and share repurchases, and declared a $0.63 quarterly dividend payable Aug. 17, 2026.
At its April 24, 2026 annual meeting, Abbott shareholders approved a new 2026 Incentive Stock Program, which replaces the 2017 program and authorizes up to 140,000,000 shares plus returned 2017 program shares. The board also added Kevin Conroy as a director and increased its size from twelve to thirteen seats, while all 12 nominees were re-elected by shareholders.
Kevin Conroy named to the Board of Directors on April 24, 2026; board size raised from 12 to 13 persons
Shareholders approved the 2026 Incentive Stock Program with 95.82 percent of votes cast in favor
Shareholders approved the advisory executive compensation vote with 90.35 percent in favor and ratified Ernst & Young LLP as auditors
Abbott disclosed that a federal court on April 10, 2026 preliminarily approved a proposed settlement of a consolidated shareholder derivative lawsuit against certain current and former directors and officers. The settlement centers on corporate governance commitments, and the defendants deny any wrongdoing; it takes effect only if the court grants final approval at a hearing on June 4, 2026.
Court preliminarily approved the proposed settlement on April 10, 2026, and set a final settlement hearing for June 4, 2026.
Abbott will maintain or adopt governance policies listed in Exhibit A to the settlement stipulation and will commit funds needed to implement them; no cash payment amount is stated.
Lead Plaintiffs' Counsel may request attorneys' fees and expenses of not more than $15.85 million, subject to court approval.
Shareholder objections and notices of intent to appear must be received by May 18, 2026.
Abbott reported first-quarter 2026 sales of $11.164 billion, up 7.8% reported and 3.7% on a comparable basis, and GAAP diluted EPS of $0.61 versus $0.76 a year earlier. The company completed its Exact Sciences acquisition on March 23, 2026, and set 2026 adjusted diluted EPS guidance of $5.38 to $5.58, including $0.20 of acquisition dilution, which shareholders will weigh against the lower GAAP earnings.
Q1 2026 GAAP net earnings were $1,077 million, down 18.7% from $1,325 million, while adjusted diluted EPS rose 5.5% to $1.15.
Specified items reduced Q1 2026 GAAP earnings by $945 million after tax, or $0.54 per share, including $422 million of intangible amortization.
Full-year 2026 comparable sales growth is projected at 6.5% to 7.5%, and second-quarter 2026 adjusted diluted EPS is projected at $1.25 to $1.31.
Abbott Laboratories completed its acquisition of Exact Sciences on March 23, 2026, under a merger agreement dated November 19, 2025. Exact Sciences shareholders received $105.00 in cash per share, and Exact Sciences is now a wholly owned Abbott subsidiary, so shareholders of both companies should watch how the combined business is integrated.
Each Exact Sciences common share was converted into the right to receive $105.00 in cash, without interest, less applicable withholding taxes.
March 20, 2026 was the last day Exact Sciences shares traded on the Nasdaq Stock Market.
Exact Sciences survives the merger as a direct, wholly owned subsidiary of Abbott.
Abbott says the deal adds Cologuard, Oncotype DX, Oncodetect and Cancerguard to its diagnostics portfolio.
Abbott Laboratories completed a $20 billion offering of senior notes on March 9, 2026, in seven fixed-rate and floating-rate series maturing between 2029 and 2066. The company said it will use the proceeds, together with cash on hand and/or additional borrowings, mainly to fund the consideration for its pending acquisition of Exact Sciences, repay certain Exact Sciences debt, and cover fees and general corporate purposes. The notes add $20 billion of debt to Abbott's balance sheet, and if the acquisition is not completed by the outside deadline, Abbott must redeem the notes at 101% of principal plus accrued interest.
Total offering of $20 billion across eight note series, with the largest series being $3.75 billion each for the 5.500% notes due 2056 and 4.650% notes due 2036
Notes were sold under a pricing agreement dated February 23, 2026, with Morgan Stanley, Barclays, BofA Securities and J.P. Morgan among the underwriters
Proceeds are earmarked for the Exact Sciences acquisition under a merger agreement dated November 19, 2025
If the acquisition is not consummated by five business days after the later of February 17, 2027 or any later agreed End Date, or Abbott notifies the trustee it will not pursue the deal, the notes must be redeemed at 101% of principal plus
Abbott agreed under a pricing agreement dated February 23, 2026, to sell $20 billion of senior notes in several series maturing from 2029 to 2066. The company said it will use the proceeds, with cash on hand and possibly additional borrowings, to pay the consideration for its acquisition of Exact Sciences, repay certain Exact Sciences debt, cover fees and expenses, and for general corporate purposes. Closing of the sale is expected on March 9, 2026, subject to customary conditions.
Total offering of $20 billion across eight series, including $1 billion of floating rate notes due 2029 and $3.75 billion each of 4.650% notes due 2036 and 5.500% notes due 2056
Proceeds intended to fund the Exact Sciences acquisition consideration and repay certain Exact Sciences indebtedness
Closing expected March 9, 2026, subject to customary closing conditions
Abbott reported fourth-quarter 2025 sales of $11.459 billion, up 4.4 percent, and adjusted diluted EPS of $1.50, up 12 percent. GAAP diluted EPS fell to $1.01 from $5.27, mainly because the prior-year quarter included a $7.497 billion non-cash tax benefit. Abbott projects 2026 organic sales growth of 6.5% to 7.5% and adjusted diluted EPS of $5.55 to $5.80.
Full-year 2025 sales were $44.3 billion, up 5.7 percent, and adjusted diluted EPS was $5.15, up 10 percent
Full-year 2025 GAAP diluted EPS was $3.72, down from $7.64 in 2024, which included a $7.497 billion non-cash tax benefit
Abbott expects first-quarter 2026 adjusted diluted EPS of $1.12 to $1.18
The pending Exact Sciences acquisition is expected to close in the second quarter of 2026
On December 12, 2025, Abbott Laboratories named Nita Ahuja, M.D. to its Board of Directors. The same day, the board amended the by-laws to set the board at thirteen persons, up from twelve, effective December 12, 2025. The filing does not describe Dr. Ahuja's background, committee roles, or compensation.
Nita Ahuja, M.D. was named to the Board of Directors on December 12, 2025.
Article III, Section 2 of the by-laws was amended so the board consists of thirteen persons, up from twelve.
The amended and restated by-laws are filed as Exhibit 99.1, effective December 12, 2025.
Abbott agreed on November 19, 2025 to acquire Exact Sciences in a cash deal valued at about $21 billion in equity and $23 billion in enterprise value, with closing expected in the second quarter of 2026. Abbott said the deal is dilutive to adjusted earnings per share through 2027 and expects it to be accretive in 2028 and beyond, so the acquisition has a near-term cost to Abbott's per-share earnings.
Exact Sciences shareholders will receive $105 per common share in cash, subject to a shareholder vote and regulatory approvals.
Abbott's adjusted EPS impact is dilutive: ($0.20) in 2026 and ($0.16) in 2027, with accretion expected in 2028.
Abbott has a $20 billion senior unsecured bridge loan commitment from Morgan Stanley Senior Funding, Inc.
Abbott expects at least $100 million in annual pre-tax synergies by 2028 and an initial 2026 adjusted gross debt-to-EBITDA ratio of about 2.7x.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Abbott Laboratories filing is on SEC EDGAR ↗. 8-K briefs of other companies →